Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis

References

• Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet371, 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Cibula D, Gompel A, Mueck AO et al. Hormonal contraception and risk of cancer. Hum. Reprod. Update16(6), 631–650 (2010).
   PubMed Web of Science ®Google Scholar
• King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302, 643–646 (2003).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med.346, 1616–1622 (2002).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl Cancer Inst.101, 80–87 (2009).
   PubMed Web of Science ®Google Scholar
• Harris RJ, Bradburn MJ, Deeks JJ et al. Metan: fixed- and random-effects meta-analysis. Stata. J.8, 3–28 (2008).
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ327, 557–560 (2003).
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata 10.1. 10.1 ed. College Station, TX, USA. StataCorp (2007).
   Google Scholar
• McLaughlin JR, Risch HA, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet Oncol.8, 26–34 (2007).
   PubMed Web of Science ®Google Scholar
• Gronwald J, Byrski T, Huzarski T et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res. Treat.95, 105–109 (2006).
   PubMed Web of Science ®Google Scholar
• Whittemore AS, Balise RR, Pharoah PD et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br. J. Cancer91, 1911–1915 (2004).
   Google Scholar
• Runnebaum IB, Wang-Gohrke S, Vesprini D et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics11, 635–638 (2001).
   Google Scholar
• Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N. Engl J. Med.339, 424–428 (1998).
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Rookus M, Andrieu N et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol. Biomarkers Prev.18, 601–610 (2009).
   PubMed Web of Science ®Google Scholar
• McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am. J. Epidemiol.160, 613–618 (2004).
   PubMed Web of Science ®Google Scholar
• Modugno F, Moslehi R, Ness RB et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control14, 439–446 (2003).
   Google Scholar
• Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl J. Med.345, 235–240 (2001).
   PubMed Web of Science ®Google Scholar
• Biglia N, Mariani L, Ponzone R, Sismondi P. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1–2 mutation carriers. Maturitas60, 71–77 (2008).
   Google Scholar
• Figueiredo JC, Bernstein L, Capanu M et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J. Clin. Oncol.26, 1411–1418 (2008).
   Google Scholar
• Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int. J. Cancer121, 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol. Diagn. Ther.11, 133–144 (2007).
   Web of Science ®Google Scholar
• Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J. Natl Cancer Inst. Monogr.16, 83–86 (2005).
   Google Scholar
• Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast14, 264–268 (2005).
   Google Scholar
• Jernstrom H, Loman N, Johannsson OT et al. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur. J. Cancer41, 2312–2320 (2005).
   PubMed Web of Science ®Google Scholar
• Kaduri L, Gibs M, Hubert A et al. Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers. Eur. J. Obstet. Gynecol. Reprod. Biol.85, 75–80 (1999).
   Google Scholar
• Haile RW, Thomas DC, McGuire V et al.BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol. Biomarkers Prev.15, 1863–1870 (2006).
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer. N. Engl J. Med.346, 2025–2032 (2002).
   PubMed Web of Science ®Google Scholar
• Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst.94, 1773–1779 (2002).
   PubMed Web of Science ®Google Scholar
• CGHFBC. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet358, 1389–1399 (2001).
   PubMed Web of Science ®Google Scholar
• Brohet RM, Goldgar DE, Easton DF et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J. Clin. Oncol.25, 3831–3836 (2007).
   PubMed Web of Science ®Google Scholar
• Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control16, 1059–1063 (2005).
   PubMed Web of Science ®Google Scholar
• Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect. Prev.26, 23–27 (2002).
   PubMedGoogle Scholar
• Grabrick DM, Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA284, 1791–1798 (2000).
   PubMed Web of Science ®Google Scholar
• Pasanisi P, Hedelin G, Berrino J et al. Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiol. Biomarkers Prev.18, 2107–2113 (2009).
   PubMed Web of Science ®Google Scholar
• Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol.26, 4282–4288 (2008).
   PubMed Web of Science ®Google Scholar
• Lee E, Ma H, McKean-Cowdin R et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol. Biomarkers Prev.17, 3170–3178 (2008).
   PubMed Web of Science ®Google Scholar
• Sade RB, Chetrit A, Figer A et al. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. Eur. J. Cancer42, 650–655 (2006).
   Web of Science ®Google Scholar
• Milne RL, Knight JA, John EM et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev.14, 350–356 (2005).
   PubMed Web of Science ®Google Scholar
• Ursin G, Henderson BE, Haile RW et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res.57, 3678–3681 (1997).
   PubMed Web of Science ®Google Scholar
• Iodice S, Barile M, Rotmensz N et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur. J. Cancer46(12), 2275–2284 (2010).
   PubMed Web of Science ®Google Scholar
• King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302, 643–646 (2003).
   PubMed Web of Science ®Google Scholar
• Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum. Reprod. Update17(1), 55–67 (2010).
   Google Scholar
• Evans DGR, Lalloo F, Ashcroft L et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol. Biomarkers Prev.18, 2318–2324 (2009).
   PubMed Web of Science ®Google Scholar
• Miller SM, Roussi P, Dally MB, Scarpato J. New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin. Cancer Res.16, 5094–5106 (2010).
   Google Scholar